NCT04843319 (VERU-100) is a Phase 1, PHASE2 clinical trial of VERU-100 in Advanced Prostate Adenocarcinoma, sponsored by Veru Inc..

Who is sponsoring NCT04843319?

NCT04843319 is sponsored by Veru Inc..

What drugs are being tested in NCT04843319?

Interventions in NCT04843319: VERU-100.

What condition does NCT04843319 study?

NCT04843319 studies Advanced Prostate Adenocarcinoma.

Is NCT04843319 still recruiting?

NCT04843319 is currently terminated. Last updated 19 May 2023.

Last reviewed 2023-05-19 · How we verify

NCT04843319: VERU-100

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

To Determine an Effective Dose of VERU-100 for the Treatment of Advanced Prostate Cancer

Terminated Phase 1, PHASE2 Last updated 19 May 2023

What this trial tests

Phase 1, PHASE2 trial testing VERU-100 in Advanced Prostate Adenocarcinoma in 24 participants. Terminated before completion.

Timeline

9 June 2021

Primary endpoint
19 January 2023

19 January 2023

Quick facts

Lead sponsor	Veru Inc.
Phase	Phase 1, PHASE2
Status	Terminated
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	24
Start date	9 June 2021
Primary completion	19 January 2023
Estimated completion	19 January 2023
Sites	11 locations across United States

Drugs / interventions tested

VERU-100 — full drug profile →

Conditions studied

Advanced Prostate Adenocarcinoma — all drugs for Advanced Prostate Adenocarcinoma →

Sponsor

Veru Inc. — full company profile →

Who can join

Adults 18 to 100, male only, with Advanced Prostate Adenocarcinoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To determine an effective dose of VERU-100 for the treatment of advanced prostate cancer by assessing its effect on testosterone levels by Day 28 and maintenance through Day 91.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Veru Inc. trials

Trials by the same sponsor.

NCT06282458 — Dose-Finding Study Evaluating Effect on Body Composition of Enobosarm in Patients Taking a GLP-1 for Chronic Weight Mgmt · Phase 2 · completed
NCT05079360 — Efficacy Evaluation of Sabizabulin Monotherapy Versus Active Control for Treatment of ER+HER2- Metastatic Breast Cancer · Phase 2 · withdrawn
NCT05065411 — Efficacy & Safety Evaluation of Enobosarm in Combo With Abemaciclib in Treatment of ER+HER2- Metastatic Breast Cancer · Phase 3 · terminated
NCT05008510 — P2 Clinical Efficacy & Safety Study of V-111 Monotherapy & Sacituzumab Govitecan-hziy/V-111 Combo Therapy for mTNBC . · Phase 2 · withdrawn
NCT04869943 — Efficacy Evaluation of Enobosarm Monotherapy in Treatment of AR+/ER+/HER2- Metastatic Breast Cancer · Phase 3 · terminated

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04843319 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Veru Inc.
Last refreshed: 19 May 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04843319.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing